Taxol formulation
First Claim
1. A pharmaceutical composition for use in treatment of cancer comprising:
- at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % anda mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective ratio of 1;
9 to 3;
7, wherein said mixture entraps said at least one taxane and said composition is in the form of particles having a size of 0.025 to 10 microns with a substantial absence of taxane crystal formation in said composition.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a pharmaceutical composition for use in treatment of cancer patients. The composition includes at least one taxane present in a pharmaceutical effective amount and a mixture of one or more negatively charged phospholipids and one or more zwitterion (i.e. uncharged) phospholipids. This mixture entraps the at least one taxane in what is believed to be a liposome. The mixture contains a ratio of negatively charged phospholipids to zwitterion phospholipids of 1:9 to 7:3. The taxol is present in an amount of 1.5-8.0 mole percent taxane. The composition is in the form of particles having a size of 0.025 to 10 microns with substantially no taxane crystals.
-
Citations
24 Claims
-
1. A pharmaceutical composition for use in treatment of cancer comprising:
-
at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective ratio of 1;
9 to 3;
7, wherein said mixture entraps said at least one taxane and said composition is in the form of particles having a size of 0.025 to 10 microns with a substantial absence of taxane crystal formation in said composition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A pharmaceutical composition for use in treatment of cancer comprising:
-
at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective ratio of 1;
9 to 3;
7, wherein said mixture forms liposomes which entrap said at least one taxane and said composition is in the form of particles having a size of 0.025 to 10 microns with a substantial absence of taxane crystal formation in said composition. - View Dependent Claims (14, 15, 16, 17, 18)
-
-
19. A pharmaceutical composition in particulate form for use in treatment of cancer comprising:
-
at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective molar ratio of 1;
9 to 3;
7, wherein said mixture entraps said at least one taxane within particles having a size of 1 to 5 microns with a substantial absence of taxane crystal formation in said composition. - View Dependent Claims (20, 21, 22, 23, 24)
-
Specification